

Andrew S Bomback

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/214719/publications.pdf>

Version: 2024-02-01

105
papers

4,398
citations

126907

33
h-index

114465

63
g-index

106
all docs

106
docs citations

106
times ranked

5135
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
2	Integrated single-cell sequencing and histopathological analyses reveal diverse injury and repair responses in a participant with acute kidney injury: a clinical-molecular-pathologic correlation. Kidney International, 2022, 101, 1116-1125.	5.2	11
3	The clinicopathologic spectrum of segmental membranous glomerulopathy. Kidney International, 2021, 99, 247-255.	5.2	30
4	Rationale and design of the Kidney Precision Medicine Project. Kidney International, 2021, 99, 498-510.	5.2	94
5	Glomerular Diseases in Diabetic Patients: Implications for Diagnosis and Management. Journal of Clinical Medicine, 2021, 10, 1855.	2.4	7
6	Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy: PRO. Kidney360, 2021, 2, 10.34067/KID.0001842021.	2.1	3
7	Late Relapses of Membranous Nephropathy: A Case Series. Kidney360, 2021, 2, 974-982.	2.1	0
8	MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	2
9	Urinary EGF and MCP-1 and risk of CKD after cardiac surgery. JCI Insight, 2021, 6, .	5.0	16
10	Belimumab in Lupus Nephritis: New Trial Results Arrive During an Exciting Time for Therapeutics. American Journal of Kidney Diseases, 2021, 77, 984-987.	1.9	2
11	Acute Hyponatremia After a Religious Fast. AACE Clinical Case Reports, 2021, 7, 236-238.	1.1	2
12	Treatment of Monoclonal Gammopathy-associated C3 Glomerulopathy With Daratumumab-based Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e674-e677.	0.4	5
13	Concurrent Anti-“Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series. American Journal of Kidney Diseases, 2021, 78, 219-225.e1.	1.9	16
14	Validation of Diagnosis Codes to Identify Infection-Related Acute Care Events in Patients With Glomerular Disease. Kidney International Reports, 2021, 6, 3079-3082.	0.8	1
15	Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. Kidney International, 2021, 100, 461-463.	5.2	87
16	Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. Kidney International, 2021, 100, 440-446.	5.2	17
17	De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?. American Journal of Kidney Diseases, 2021, 78, 477-480.	1.9	95
18	Longitudinal Outcomes of COVID-19-Associated Collapsing Glomerulopathy and Other Podocytopathies. Journal of the American Society of Nephrology: JASN, 2021, 32, 2958-2969.	6.1	31

#	ARTICLE	IF	CITATIONS
19	Proposal for a more practical classification of antineutrophil cytoplasmic antibody-associated vasculitis. CKJ: Clinical Kidney Journal, 2021, 14, 1327-1334.	2.9	0
20	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1833-1839.	4.5	27
21	Use of ofatumumab and eplerenone in posttransplant recurrence of FSGS. Pediatric Transplantation, 2021, , e14191.	1.0	3
22	Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1595-1602.	4.5	103
23	Infection-Related Acute Care Events among Patients with Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1749-1761.	4.5	14
24	The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney International, 2020, 97, 1006-1016.	5.2	40
25	Postmortem Kidney Pathology Findings in Patients with COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 2158-2167.	6.1	241
26	Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series. American Journal of Kidney Diseases, 2020, 76, 374-383.	1.9	21
27	Ask and It Shall Be Given. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 594-596.	4.5	0
28	Pilot Study of Return of Genetic Results to Patients in Adult Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 651-664.	4.5	28
29	C3 Glomerulopathy: Pathogenesis and Treatment. Advances in Chronic Kidney Disease, 2020, 27, 104-110.	1.4	17
30	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	12.8	120
31	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.8	2
32	Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020. American Journal of Kidney Diseases, 2020, 75, 955-964.	1.9	46
33	How COVID-19 Has Changed the Management of Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 876-879.	4.5	23
34	The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1066-1072.	4.5	17
35	Glomerular Diseases in Patients with Diabetes Mellitus: An Underappreciated Epidemic. Kidney360, 2020, 1, 220-222.	2.1	9
36	Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?. Pediatric Nephrology, 2020, 35, 1791-1795.	1.7	1

#	ARTICLE	IF	CITATIONS
37	In Search of C3G Tissue Biomarkers. <i>Kidney International Reports</i> , 2019, 4, 1359-1361.	0.8	3
38	Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN). <i>Kidney International Reports</i> , 2019, 4, 1725-1734.	0.8	13
39	Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1605-1615.	4.5	37
40	The spectrum of kidney biopsy findings in patients with morbid obesity. <i>Kidney International</i> , 2019, 95, 647-654.	5.2	32
41	Rituximab for Anti-GBM Glomerular Basement Membrane Disease. <i>Kidney International Reports</i> , 2019, 4, 614-618.	0.8	16
42	Lupus Podocytopathy: An Overview. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 369-375.	1.4	25
43	Shortening the Duration of Corticosteroid Exposure in Minimal Change Disease: Can We Treat Adults Like Children?. <i>American Journal of Nephrology</i> , 2019, 49, 52-53.	3.1	2
44	Kidney Transplantation in C3 Glomerulopathy: A Case Series. <i>American Journal of Kidney Diseases</i> , 2019, 73, 316-323.	1.9	48
45	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	1.9	68
46	Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience. <i>Blood</i> , 2019, 134, 5565-5565.	1.4	0
47	Management of Membranous Nephropathy in the PLA2R Era. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 784-786.	4.5	18
48	Membranous Nephropathy in a Patient With Common Variable Immune Deficiency. <i>Kidney International Reports</i> , 2018, 3, 738-742.	0.8	2
49	Precision Medicine for Acute Kidney Injury (AKI): Redefining AKI by Agnostic Kidney Tissue Interrogation and Genetics. <i>Seminars in Nephrology</i> , 2018, 38, 40-51.	1.6	28
50	Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 406-413.	4.5	63
51	C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. <i>Kidney International</i> , 2018, 93, 977-985.	5.2	123
52	Membranous nephropathy and cancer in the era of PLA2R testing. <i>Journal of Onco-Nephrology</i> , 2018, 2, 50-55.	0.6	1
53	A Three-Headed Approach to Kidney Involvement in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, xiii-xiv.	1.9	0
54	Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. <i>Kidney International</i> , 2018, 94, 1189-1198.	5.2	36

#	ARTICLE	IF	CITATIONS
55	An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?. American Journal of Kidney Diseases, 2018, 72, 758-760.	1.9	10
56	Nonproliferative Forms of Lupus Nephritis. Rheumatic Disease Clinics of North America, 2018, 44, 561-569.	1.9	11
57	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39
58	Membranous Nephropathy: Approaches to Treatment. American Journal of Nephrology, 2018, 47, 30-42.	3.1	48
59	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. Current Hypertension Reports, 2018, 20, 75.	3.5	62
60	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. Annals of Internal Medicine, 2018, 168, 100.	3.9	154
61	An Elderly Man with Fatigue, Dyspnea, and Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 836-838.	4.5	2
62	A Pregnant Woman with Lupus and Nephrotic-Range Proteinuria. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1534-1537.	4.5	1
63	Aldosterone breakthrough does not alter central hemodynamics. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2017, 18, 147032031773500.	1.7	2
64	Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways. Kidney International Reports, 2016, 1, 148-155.	0.8	39
65	Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. Blood Purification, 2016, 41, 166-170.	1.8	26
66	Phosphate enemas and GFR decline: it's premature to sound the alarm. Kidney International, 2016, 90, 13-15.	5.2	1
67	American Society of Nephrology Quiz and Questionnaire 2015: Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 884-890.	4.5	1
68	Aldosterone Blockade in CKD: Emphasis on Pharmacology. Advances in Chronic Kidney Disease, 2015, 22, 123-132.	1.4	27
69	Drug-Induced Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1291-1299.	4.5	80
70	Eculizumab in the Treatment of Membranoproliferative Glomerulonephritis. Nephron Clinical Practice, 2015, 128, 270-276.	2.3	165
71	Evaluation of the Scored Questionnaire to Identify Individuals with Chronic Kidney Disease in a Community-based Screening Program in Rural North Carolina. , 2014, s2, 007.		3
72	Rituximab treatment for fibrillary glomerulonephritis. Nephrology Dialysis Transplantation, 2014, 29, 1925-1931.	0.7	47

#	ARTICLE	IF	CITATIONS
73	Toward a working definition of C3 glomerulopathy by immunofluorescence. <i>Kidney International</i> , 2014, 85, 450-456.	5.2	164
74	Use of Bortezomib in Heavy-Chain Deposition Disease: Report of 3 Cases. <i>American Journal of Kidney Diseases</i> , 2014, 64, 123-127.	1.9	15
75	Sodium Phosphate Does Not Increase Risk for Acute Kidney Injury After Routine Colonoscopy, Compared With Polyethylene Glycol. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1514-1521.e3.	4.4	20
76	Anti-Complement Therapy for Glomerular Diseases. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 152-158.	1.4	15
77	The Evolution of Treating Glomerular Diseases: Letting Science Lead the Way. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 119-120.	1.4	0
78	Definition, identification and treatment of resistant hypertension in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1327-1335.	0.7	21
79	Aldosterone Blockade in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2014, 34, 307-322.	1.6	20
80	ANCA-associated GN to PLEX or not to PLEX?. <i>Nature Reviews Nephrology</i> , 2013, 9, 436-438.	9.6	4
81	The Modern Spectrum of Renal Biopsy Findings in Patients with Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1718-1724.	4.5	227
82	Ancestry, genetic risk and health disparities. <i>Nature Reviews Nephrology</i> , 2013, 9, 699-700.	9.6	4
83	Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 748-756.	4.5	295
84	Mineralocorticoid Receptor Blockade in Chronic Kidney Disease. <i>Blood Purification</i> , 2012, 33, 119-124.	1.8	26
85	Anti-glomerular basement membrane nephritis: why we still 'need' the kidney biopsy. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 496-497.	2.9	7
86	Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 338-345.	2.3	35
87	Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. <i>Nature Reviews Nephrology</i> , 2012, 8, 634-642.	9.6	131
88	Renal Biopsy in the Elderly and Very Elderly: Useful or Not?. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 61-67.	1.4	20
89	Treatment of Resistant Glomerular Diseases with Adrenocorticotrophic Hormone Gel: A Prospective Trial. <i>American Journal of Nephrology</i> , 2012, 36, 58-67.	3.1	83
90	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH) gel. <i>Drug Design, Development and Therapy</i> , 2011, 5, 147.	4.3	83

#	ARTICLE	IF	CITATIONS
91	ANCA-associated glomerulonephritis in the very elderly. <i>Kidney International</i> , 2011, 79, 757-764.	5.2	77
92	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH). <i>Discovery Medicine</i> , 2011, 12, 91-6.	0.5	22
93	Racial Differences in Kidney Function Among Individuals With Obesity and Metabolic Syndrome: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010, 55, S4-S14.	1.9	19
94	Updates on the Treatment of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 2028-2035.	6.1	152
95	Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. <i>Kidney International</i> , 2010, 77, 609-616.	5.2	124
96	Gestational Diabetes Mellitus Alone in the Absence of Subsequent Diabetes Is Associated With Microalbuminuria. <i>Diabetes Care</i> , 2010, 33, 2586-2591.	8.6	38
97	A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3442-3446.	0.7	21
98	Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. <i>American Journal of Hypertension</i> , 2009, 22, 1032-1040.	2.0	46
99	Interaction of Aldosterone and Extracellular Volume in the Pathogenesis of Obesity-Associated Kidney Disease: A Narrative Review. <i>American Journal of Nephrology</i> , 2009, 30, 140-146.	3.1	40
100	Disordered aldosterone-volume relationship in end-stage kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 230-236.	1.7	27
101	Sugar-sweetened beverage consumption and the progression of chronic kidney disease in the Multi-Ethnic Study of Atherosclerosis (MESA). <i>American Journal of Clinical Nutrition</i> , 2009, 90, 1172-1178.	4.7	27
102	Some of the People All of the Time, All of the People None of the Time. <i>American Journal of Kidney Diseases</i> , 2009, 54, A33-A35.	1.9	3
103	Colonic necrosis due to sodium polystyrene sulfate (Kayexalate). <i>American Journal of Emergency Medicine</i> , 2009, 27, 753.e1-753.e2.	1.6	21
104	Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?. <i>Nature Clinical Practice Nephrology</i> , 2009, 5, 74-75.	2.0	19
105	Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2008, 51, 199-211.	1.9	211